Selected Presentations at Scientific and Professional Meetings

Click here for a list of the most recent and future presentations on psychedelic economics

“The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD”; American Society of clinical psychopharmacology 2021 Annual Meeting; June 1 – 4, 2021.

“Is MDMA-assisted therapy for severe, chronic, treatment-resistant PTSD, cost-effective?” Psychedelic and Entheogen Academic  Council  - UCSF; November 6, 2020.

“Hepatitis B prevalence association with current and past sexually transmitted infections: A systematic review and meta-analysis.” U.S, Center for disease Control and Prevention. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Epidemiologic and Economic Modeling Agreement (NEEMA); August 16, 2019.

“Cost-effectiveness of MDMA-assisted psychotherapy for PTSD: Progress report”, Multi-Disciplinary Association for Psychedelic Studies (MAPS); Board Meeting, Vista, CA, July 24, 2019.

“Methods for an Exploratory Cost-Effectiveness Analysis of the MP18 Regimen”, Multi-Disciplinary Association for Psychedelic Studies (MAPS); Pre-Board Meeting, San Francisco, February 27, 2019.

“Ethics & Efficiency Choices in Portfolio Design”.  Sixth Annual UCSF Global Health Economics Consortium, (GHECon), “The Economics of Non-Communicable Diseases”, University of California, San Francisco, May 3, 2019.

“The Ethical Foundations of Cost-Effectiveness Analysis”.  Fourth Annual UCSF Global Health Economics Consortium, (GHECon), “The Economics of Non-Communicable Diseases”, University of California, San Francisco, February 10, 2017.

“Summary of Systematic Review and Meta-Analysis of School-Based Programs to Prevent Pregnancy in High-Risk Youth”. Consortium for Assessment of Prevention Economics (CAPE), CDC Econ CoAg TB Modeling Meeting, March 15-16, 2016

“Cost-Effectiveness Thresholds, Priority-Setting for UHC, and the new HCV Medications”. Prince Mahidol Award Conference Bangkok, January 30, 2016

Gestational Diabetes Formulas for Cost-Effectiveness Model and the FIGO GDM Initiative: Supporting evidence-based screening and treatment FIGO World Congress of Gynecology and Obstetrics. Vancouver, Canada, October 4 – 9, 2015.

“The Problem with Thresholds in Evaluating the Cost-Effectiveness of Global Health Programs”, Webinar on Cost-Effectiveness Thresholds, Center for Global Development, Washington, DC, June 4, 2015.

“Gestational Diabetes Formulas for Cost-Effectiveness (GeDiForCE) Model and the FIGO GDM Initiative: Supporting evidence-based screening and treatment”.  8th International Symposium on Diabetes, Hypertension, Metabolic Syndrome and Pregnancy, Berlin, April 16, 2015. 

“The Cost-Effectiveness of Essential Surgery in Developing Countries”. Grand Rounds, Department of Surgery, University of California, San Francisco, January 28, 2015.

“The Cost-Effectiveness of New Therapies for Hepatitis C”.  Second Annual UCSF Global Health Economics Consortium, (GHECon), University of California, San Francisco, November 21, 2014.

“Costs and Health Impact of Screening and Treating Gestational Diabetes Mellitus: Using the GeDiForCE model to evaluate national policy options”; 7th International DIP Symposium on Diabetes, Hypertension, Metabolic Syndrome, and Pregnancy (DIP 2013), Florence, Italy, March 13, 2013.

“Taking ART to Scale: Determinants of the Cost and Cost-Effectiveness of Antiretroviral Therapy in 45 Clinical Sites in Zambia”.  International AIDS Economics Network Pre-Conference Meeting. Washington DC, July 20, 2012.

“The Cost-Effectiveness of Adding a Third HIV Test in Routine HIV Testing to Reduce the Frequency of False Positive Test Results in Sub-Saharan Africa”. International AIDS Economics Network Pre-Conference Meeting. Washington DC, July 20, 2012.

“Cost-effectiveness of gestational diabetes mellitus screening, management and lifestyle intervention in India and Israel”. Mount Hood Challenge, Baltimore. MD. June 7-8, 2012. 

“Introducing the GDModel for Assessing Gestational Diabetes Screening and Treatment”, Diabetes in Pregnancy Study Group – India; DIPSI – 2011, Mumbai, India, February 25, 2011.

“Enhancing the Cost-Effectiveness of HIV Prevention in Kenya East African Community HIV Prevention Expert Think Tank Meeting”. February 2009, Nairobi, Kenya.

“The cost and efficiency of HRSA’s SPNS PwP program”, Special Projects of National Significance and the University of California, San Francisco’s Enhancing Prevention with Positives Evaluation Center
7th Grantee Meeting; May 2007, San Francisco, CA.

“HIV/AIDS Interventions in Resource-Scarce Settings: Using Cost Benefit and Cost Effectiveness Analysis to Help Guide Policy and Action”.  Harvard School of Public Health, Cambridge, MA, September, 2006.

“Cost-Effectiveness Analysis and Cost Data”; Application to EPPEC Special Projects of National Significance and the University of California, San Francisco’s Enhancing Prevention with Positives Evaluation Center; Second Grantee Meeting; Chicago, IL, May, 2004.

 “The awkward role of CEA in International HIV/AIDS Control”, J.G. Kahn, E. Marseille (co-author but not presenter), New York Academy of Science, and Yale University, March 27, 2003.

“Cost-effectiveness of nevirapine provision with and without serotesting”. Consultative Meeting on the Use of Nevirapine for the Prevention of Mother-to-Child Transmission of HIV among Women of Unknown Serostatus, WHO, Geneva, 2001

“Scaling-up Prevention of Mother-to-Child Transmission of HIV in Uganda”, E. Marseille, Technical Consultation for Global Fund to Fight AIDS, Tuberculosis and Malaria, Johns Hopkins University, Center for AIDS Research, October, 2001

Marseille E. Countywide implementation of mother to child HIV prevention programs [abstract 098]. Presented at the Third Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants. Kampala, Uganda, September, 2001.

“Economic Appraisal of HIV Prevention Programs in Developing Countries: Describing Cost Functions”, E. Marseille, UNAIDS Reference Group on Economics, Cuernavaca, Mexico, February, 2001.

“Cost-Effectiveness of the Female Condom in Preventing HIV and STDs in Commercial Sex Workers in Rural South Africa”, E. Marseille, 13th World AIDS Conference; Durban, South Africa, July 2000.

“The Costs and Benefits of Employer-Sponsored HIV treatment in a Ugandan Corporation”, E. Marseille, J.G. Kahn, S. Saba, 13th World AIDS Conference; Durban, South Africa, July, 2000.

“Preventing Mother to Child Transmission of HIV”, E. Marseille, Third International HIV Prevention Works Symposium; Durban, South Africa, July, 2000.

“Cost-Benefit Models of HIV/AIDS Interventions” E. Marseille, Symposium entitled “HIV Non-Intervention: A Costly Option”, 13th World AIDS Conference; Durban, South Africa, July, 2000.

“Economic Analysis of HIVNET 012 Results – Implications for Policy Decisions”, E. Marseille, Managing HIV in the 21st Century; Tormina, Italy, March, 2000. 

“Cost effectiveness of single-dose nevirapine regimen for mothers and infants to decrease vertical HIV-1 transmission in sub-Saharan Africa”, E. Marseille, Second Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants; Montreal, September, 1999.

“Applying a User-Friendly Computer Model to Assess the Cost-Effectiveness of Mother-to-Child HIV Transmission Interventions”, E. Marseille, Second Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants; Montreal, September, 1999.